Washington, D.C. | December 30, 2025 — Vanda Pharmaceuticals Inc. has announced U.S. Food and Drug Administration (FDA) approval of NEREUS™ (tradipitant) for the prevention of vomiting induced by motion, marking the first new pharmacologic treatment for motion sickness in more than 40 years. The approval represents a major scientific and regulatory milestone, validating modern neuropharmacology approaches to a long-recognized yet underserved condition that affects both civilian populations and military operational readiness.
Science Significance
From a scientific perspective, NEREUS™ (tradipitant) is a selective neurokinin-1 (NK-1) receptor antagonist that targets the substance P signaling pathway, a central mechanism responsible for nausea and vomiting triggered by sensory conflict between vestibular, visual, and proprioceptive inputs. Unlike older motion sickness therapies that rely on anticholinergic or antihistaminic effects, tradipitant directly modulates central emetic signaling, representing a mechanism-based advancement. Its approval is supported by three robust clinical trials, including two pivotal Phase 3 real-world provocation studies conducted in maritime environments, demonstrating statistically significant reductions in vomiting incidence and consistent efficacy across populations.
Regulatory Significance
The FDA approval of NEREUS™ reflects successful compliance across the full cGxP lifecycle, including Good Clinical Practice (GCP)-driven Phase 3 trials, rigorous safety evaluation, and comprehensive regulatory review. As the first FDA-approved NK-1 receptor antagonist specifically indicated for motion-induced vomiting, the decision establishes a new regulatory benchmark for therapies targeting acute emetic conditions. This milestone also underscores the FDA’s willingness to approve novel central nervous system therapies when supported by well-designed real-world clinical evidence, reinforcing regulatory confidence in modern trial methodologies.
Business Significance
Advertisement
From a business standpoint, FDA approval positions NEREUS™ as a first-in-class commercial asset within a large and historically under-innovated market. Motion sickness affects tens of millions of individuals annually, many of whom rely on over-the-counter products with limited efficacy or tolerability. With a near-term commercial launch anticipated, Vanda Pharmaceuticals strengthens its revenue diversification strategy and reinforces its profile as a company capable of translating complex neuroscience into approved therapies. Additionally, the validated NK-1 platform creates future lifecycle expansion opportunities, supporting ongoing development programs in gastroparesis and treatment-related nausea.
Patients’ Significance
For patients, the approval of NEREUS™ represents meaningful progress in quality-of-life improvement. Motion sickness can range from mild discomfort to severe, recurrent vomiting that limits travel, occupational performance, and daily activities. Many patients discontinue existing therapies due to sedation or inadequate symptom control. NEREUS™ offers a targeted, evidence-based option that demonstrated risk reductions exceeding 50–70% in vomiting incidence in clinical studies, providing patients with a new standard of preventive care grounded in modern neurobiology.
Policy Significance
At the policy level, the approval highlights the importance of continued innovation in common but under-prioritized conditions. Motion sickness has historically impacted military readiness, transportation safety, and workforce productivity, yet saw limited therapeutic progress for decades. This decision aligns with broader healthcare policy goals that encourage innovation in neuroscience, improved tolerability profiles, and expanded access to preventive therapies. It also supports regulatory frameworks that recognize the value of real-world clinical trial settings in evaluating treatment effectiveness.
In summary, the FDA approval of NEREUS™ marks a transformational moment at the intersection of neuroscience, regulatory science, and patient care. By introducing the first new pharmacologic option for motion-induced vomiting in over four decades, Vanda Pharmaceuticals has advanced both scientific understanding and therapeutic standards for a widespread condition. For the cGxP.wire audience, this milestone exemplifies how rigorous clinical development, regulatory excellence, and mechanism-driven innovation can converge to deliver meaningful new therapies to patients and set new benchmarks in pharmaceutical advancement.
Source: Vanda Pharmaceuticals Inc. press release
